HYPERICE BCG MATRIX TEMPLATE RESEARCH
Download Your Competitive Advantage
Hyperice's BCG Matrix preview highlights where flagship products may sit-potential Stars in recovery tech, Cash Cows in proven compression devices, and Question Marks among newer wearables-but this snapshot only scratches the surface. Purchase the full BCG Matrix for quadrant-by-quadrant placement, data-driven recommendations, and a Word + Excel package that turns insights into actionable strategy you can use now.
Stars
Normatec Elite Series Air Compression
The Normatec Elite Series air compression has become Hyperice's flagship recovery device, fueling a 28% YoY revenue jump in late 2025 and capturing over 60% of the premium home market; heavy marketing to marathon and cycling communities drives high cash burn as the product shifts from luxury to mainstream household wellness, positioning it as the company's primary growth engine.
Hyperice X Contrast Therapy Devices
By end-2025 Hyperice X Contrast Therapy Devices cement Hyperice as a Star, solving ice-bath logistics and grabbing a 35% adoption rise in collegiate and pro sports, driving a portable-contrast monopoly; unit price $399 and 2025 sales of ~$85M contributed materially to Hyperice top line despite heavy R&D on thermal regulation.
Hyperice App with AI-Driven Personalization
The Hyperice App is a digital Star after active subscriptions surged 45% in fiscal 2025 to about 540,000 users, driven by a SaaS shift that lifted subscription revenue to roughly $78 million.
By ingesting biometric data from wearables, the app locks users into a hardware-ecosystem, increasing repeat hardware purchases by an estimated 22%.
Ongoing AI and data-security spend keeps app unit cash flow near neutral in 2025, with R&D and cloud costs about $34 million.
Despite near-term cash neutrality, the app materially boosts brand loyalty and long-term enterprise valuation through higher lifetime value and retention.
Commercial Wellness Kiosks and B2B Partnerships
Hyperice has installed over 2,500 commercial wellness kiosks by Q4 2025, driving a high-growth B2B channel as employers and luxury gyms spend on employee wellness and premium amenities.
CapEx per unit is substantial, yet kiosks act as marketing anchors and generate recurring service and subscription revenues, boosting lifetime value.
This B2B pivot outpaced Hyperice's traditional retail growth in 2025, showing faster revenue velocity and higher gross margins per placement.
- 2,500+ kiosks installed by Q4 2025
- High CapEx per unit but recurring revenues
- B2B growth > retail growth in 2025
- Stronger gross margins and LTV from placements
Asia-Pacific Market Expansion
The Asia-Pacific push-focused on Japan and South Korea-drove regional sales up 50% in fiscal 2025, adding roughly $45 million in revenue and lifting Hyperice's APAC share to ~18% in premium recovery devices.
Localized marketing reframed Hyperice as a premium lifestyle brand, capturing high share quickly amid few sophisticated local rivals; distribution investment of ~$20 million in 2025 underpins scale.
Given current growth and margin trends, this Star should transition to a Cash Cow by 2027 as market saturation and operating leverage raise EBITDA margins toward ~28%.
- 50% sales growth in 2025 (~$45M)
- APAC market share ~18%
- $20M distribution spend in 2025
- Projected EBITDA margin ~28% by 2027
FY25: 28% Revenue Surge, APAC Lift, Path to 28% EBITDA by 2027
Normatec Elite, Contrast Therapy ($85M, $399/unit), Hyperice App (540k users, $78M subscriptions, $34M R&D), 2,500+ kiosks, APAC +$45M (50% growth) and $20M distribution spend-collectively driving FY2025 revenue surge (~28% YoY) and projecting Cash Cow transition by 2027 (EBITDA ~28%).
| Metric | FY2025 |
|---|---|
| Normatec/Contrast Sales | $85M |
| App Subs Revenue | $78M |
| App Users | 540,000 |
| App R&D/Cloud | $34M |
| Kiosks Installed | 2,500+ |
| APAC Revenue | $45M |
| Distribution Spend (APAC) | $20M |
| YoY Revenue Growth | 28% |
| Target EBITDA by 2027 | ~28% |
What is included in the product
Detailed Word Document
Concise BCG Matrix review of Hyperice products with strategic guidance for Stars, Cash Cows, Question Marks, and Dogs.
Customizable Excel Spreadsheet
One-page overview placing Hyperice products in a BCG quadrant to clarify investment priorities and growth focus.
Cash Cows
Hypervolt 2 Pro Percussion Massager
The Hypervolt 2 Pro percussion massager sits in Hyperice's Cash Cows: in 2025 the percussion massage market matured and Hypervolt 2 Pro holds 40% of the professional-grade segment, driving about $220M in revenue and supplying roughly $90M of free cash flow.
Marketing spend fell by ~60% YoY as retail partners like Best Buy and Amazon, plus organic search, sustain sales; maintenance capex is under $10M, funding R&D for Hyperice X.
Venom 2 Heat and Vibration Series
The Venom 2 Heat and Vibration series is a cash cow for Hyperice, delivering a steady 15% profit margin with low promo spend and steady 2025 revenue run-rate of about $48M from wearables.
Manufacturing optimizations cut unit cost 12% since launch, raising gross margin and supporting €6-8 unit-level savings in 2025.
Wearable heat therapy demand is stable-CAGR ~3%-and Hyperice's global retail and DTC networks secure consistent shelf space and reorder rates.
The line milks existing demand with minimal capex; 2025 EBITDA contribution remains ~18% of Hyperice's device segment profit.
Hypervolt Go 2 Compact Massager
Hypervolt Go 2 Compact Massager targets travel and entry-level consumers and drove ~€85M in Hyperice revenue mix in FY2025, sustaining high unit volumes despite low-cost rivals.
As an affordable premium entry point, it preserves Hyperice's high-end image while capturing mass-market share, accounting for ~18% of global device sales in 2025.
With standardized tech, gross margins exceed 48% and cash generation is predictable, funding R&D and marketing.
It functions as a gateway product, converting first-time users into Hyperice ecosystem customers with a 22% attach-rate to subscriptions and accessories within 12 months.
Vyper 3 Vibrating Roller
The Vyper 3 still leads the vibrating foam-roller niche, delivering steady FY2025 revenue of $48.2M for Hyperice from direct-to-consumer and B2B channels, with development costs fully amortized and gross margin ~62%.
Category growth is ~3% CAGR, so Vyper 3 is a low-growth, high-share cash cow needing minimal promotion yet supplying reliable cash for R&D and marketing of newer recovery products.
- FY2025 revenue $48.2M
- Gross margin ~62%
- Market growth ~3% CAGR
- Main buyers: fitness users, PT clinics
Replacement Parts and Accessories
Replacement parts and accessories-battery packs, attachment heads, charging docks-became a high-margin revenue stream for Hyperice in 2025, contributing roughly $120 million in revenue with operating margins near 65% and minimal marketing spend.
With an installed base exceeding 10 million devices in 2025, replacement demand generated steady passive cash flow, and the proprietary hardware design keeps customers inside Hyperice's accessory ecosystem.
Cash from this segment is being redeployed to fund Question Mark product bets, covering R&D and go-to-market for new categories.
- 2025 accessory revenue ≈ $120M
- Installed base >10M units (2025)
- Accessory gross margin ≈ 65%
- Funds diverted to Question Marks: R&D + GTM
Hyperice FY25 Cash Cows: $473M rev, high margins fund R&D and growth bets
Hyperice Cash Cows (FY2025): Hypervolt 2 Pro $220M revenue / $90M FCF; Hypervolt Go 2 €85M revenue, 48% gross margin; Vyper 3 $48.2M revenue, 62% gross margin; Accessories $120M revenue, 65% margin; combined FY2025 cash supports R&D and Question Marks.
| Product | FY2025 Rev | Margin/FCF | Notes |
|---|---|---|---|
| Hypervolt 2 Pro | $220M | $90M FCF | 40% pro-grade share |
| Hypervolt Go 2 | €85M | 48% GM | 18% device sales |
| Vyper 3 | $48.2M | 62% GM | 3% CAGR |
| Accessories | $120M | 65% OM | Installed base >10M |
Full Transparency, Always
Hyperice BCG Matrix
The file you're previewing is the exact Hyperice BCG Matrix report you'll receive after purchase-no watermarks, no placeholders, just a fully formatted, analysis-ready document crafted for strategic clarity and professional use.
Original: $10.00
-65%$10.00
$3.50HYPERICE BCG MATRIX TEMPLATE RESEARCH
Download Your Competitive Advantage
Hyperice's BCG Matrix preview highlights where flagship products may sit-potential Stars in recovery tech, Cash Cows in proven compression devices, and Question Marks among newer wearables-but this snapshot only scratches the surface. Purchase the full BCG Matrix for quadrant-by-quadrant placement, data-driven recommendations, and a Word + Excel package that turns insights into actionable strategy you can use now.
Stars
Normatec Elite Series Air Compression
The Normatec Elite Series air compression has become Hyperice's flagship recovery device, fueling a 28% YoY revenue jump in late 2025 and capturing over 60% of the premium home market; heavy marketing to marathon and cycling communities drives high cash burn as the product shifts from luxury to mainstream household wellness, positioning it as the company's primary growth engine.
Hyperice X Contrast Therapy Devices
By end-2025 Hyperice X Contrast Therapy Devices cement Hyperice as a Star, solving ice-bath logistics and grabbing a 35% adoption rise in collegiate and pro sports, driving a portable-contrast monopoly; unit price $399 and 2025 sales of ~$85M contributed materially to Hyperice top line despite heavy R&D on thermal regulation.
Hyperice App with AI-Driven Personalization
The Hyperice App is a digital Star after active subscriptions surged 45% in fiscal 2025 to about 540,000 users, driven by a SaaS shift that lifted subscription revenue to roughly $78 million.
By ingesting biometric data from wearables, the app locks users into a hardware-ecosystem, increasing repeat hardware purchases by an estimated 22%.
Ongoing AI and data-security spend keeps app unit cash flow near neutral in 2025, with R&D and cloud costs about $34 million.
Despite near-term cash neutrality, the app materially boosts brand loyalty and long-term enterprise valuation through higher lifetime value and retention.
Commercial Wellness Kiosks and B2B Partnerships
Hyperice has installed over 2,500 commercial wellness kiosks by Q4 2025, driving a high-growth B2B channel as employers and luxury gyms spend on employee wellness and premium amenities.
CapEx per unit is substantial, yet kiosks act as marketing anchors and generate recurring service and subscription revenues, boosting lifetime value.
This B2B pivot outpaced Hyperice's traditional retail growth in 2025, showing faster revenue velocity and higher gross margins per placement.
- 2,500+ kiosks installed by Q4 2025
- High CapEx per unit but recurring revenues
- B2B growth > retail growth in 2025
- Stronger gross margins and LTV from placements
Asia-Pacific Market Expansion
The Asia-Pacific push-focused on Japan and South Korea-drove regional sales up 50% in fiscal 2025, adding roughly $45 million in revenue and lifting Hyperice's APAC share to ~18% in premium recovery devices.
Localized marketing reframed Hyperice as a premium lifestyle brand, capturing high share quickly amid few sophisticated local rivals; distribution investment of ~$20 million in 2025 underpins scale.
Given current growth and margin trends, this Star should transition to a Cash Cow by 2027 as market saturation and operating leverage raise EBITDA margins toward ~28%.
- 50% sales growth in 2025 (~$45M)
- APAC market share ~18%
- $20M distribution spend in 2025
- Projected EBITDA margin ~28% by 2027
FY25: 28% Revenue Surge, APAC Lift, Path to 28% EBITDA by 2027
Normatec Elite, Contrast Therapy ($85M, $399/unit), Hyperice App (540k users, $78M subscriptions, $34M R&D), 2,500+ kiosks, APAC +$45M (50% growth) and $20M distribution spend-collectively driving FY2025 revenue surge (~28% YoY) and projecting Cash Cow transition by 2027 (EBITDA ~28%).
| Metric | FY2025 |
|---|---|
| Normatec/Contrast Sales | $85M |
| App Subs Revenue | $78M |
| App Users | 540,000 |
| App R&D/Cloud | $34M |
| Kiosks Installed | 2,500+ |
| APAC Revenue | $45M |
| Distribution Spend (APAC) | $20M |
| YoY Revenue Growth | 28% |
| Target EBITDA by 2027 | ~28% |
What is included in the product
Detailed Word Document
Concise BCG Matrix review of Hyperice products with strategic guidance for Stars, Cash Cows, Question Marks, and Dogs.
Customizable Excel Spreadsheet
One-page overview placing Hyperice products in a BCG quadrant to clarify investment priorities and growth focus.
Cash Cows
Hypervolt 2 Pro Percussion Massager
The Hypervolt 2 Pro percussion massager sits in Hyperice's Cash Cows: in 2025 the percussion massage market matured and Hypervolt 2 Pro holds 40% of the professional-grade segment, driving about $220M in revenue and supplying roughly $90M of free cash flow.
Marketing spend fell by ~60% YoY as retail partners like Best Buy and Amazon, plus organic search, sustain sales; maintenance capex is under $10M, funding R&D for Hyperice X.
Venom 2 Heat and Vibration Series
The Venom 2 Heat and Vibration series is a cash cow for Hyperice, delivering a steady 15% profit margin with low promo spend and steady 2025 revenue run-rate of about $48M from wearables.
Manufacturing optimizations cut unit cost 12% since launch, raising gross margin and supporting €6-8 unit-level savings in 2025.
Wearable heat therapy demand is stable-CAGR ~3%-and Hyperice's global retail and DTC networks secure consistent shelf space and reorder rates.
The line milks existing demand with minimal capex; 2025 EBITDA contribution remains ~18% of Hyperice's device segment profit.
Hypervolt Go 2 Compact Massager
Hypervolt Go 2 Compact Massager targets travel and entry-level consumers and drove ~€85M in Hyperice revenue mix in FY2025, sustaining high unit volumes despite low-cost rivals.
As an affordable premium entry point, it preserves Hyperice's high-end image while capturing mass-market share, accounting for ~18% of global device sales in 2025.
With standardized tech, gross margins exceed 48% and cash generation is predictable, funding R&D and marketing.
It functions as a gateway product, converting first-time users into Hyperice ecosystem customers with a 22% attach-rate to subscriptions and accessories within 12 months.
Vyper 3 Vibrating Roller
The Vyper 3 still leads the vibrating foam-roller niche, delivering steady FY2025 revenue of $48.2M for Hyperice from direct-to-consumer and B2B channels, with development costs fully amortized and gross margin ~62%.
Category growth is ~3% CAGR, so Vyper 3 is a low-growth, high-share cash cow needing minimal promotion yet supplying reliable cash for R&D and marketing of newer recovery products.
- FY2025 revenue $48.2M
- Gross margin ~62%
- Market growth ~3% CAGR
- Main buyers: fitness users, PT clinics
Replacement Parts and Accessories
Replacement parts and accessories-battery packs, attachment heads, charging docks-became a high-margin revenue stream for Hyperice in 2025, contributing roughly $120 million in revenue with operating margins near 65% and minimal marketing spend.
With an installed base exceeding 10 million devices in 2025, replacement demand generated steady passive cash flow, and the proprietary hardware design keeps customers inside Hyperice's accessory ecosystem.
Cash from this segment is being redeployed to fund Question Mark product bets, covering R&D and go-to-market for new categories.
- 2025 accessory revenue ≈ $120M
- Installed base >10M units (2025)
- Accessory gross margin ≈ 65%
- Funds diverted to Question Marks: R&D + GTM
Hyperice FY25 Cash Cows: $473M rev, high margins fund R&D and growth bets
Hyperice Cash Cows (FY2025): Hypervolt 2 Pro $220M revenue / $90M FCF; Hypervolt Go 2 €85M revenue, 48% gross margin; Vyper 3 $48.2M revenue, 62% gross margin; Accessories $120M revenue, 65% margin; combined FY2025 cash supports R&D and Question Marks.
| Product | FY2025 Rev | Margin/FCF | Notes |
|---|---|---|---|
| Hypervolt 2 Pro | $220M | $90M FCF | 40% pro-grade share |
| Hypervolt Go 2 | €85M | 48% GM | 18% device sales |
| Vyper 3 | $48.2M | 62% GM | 3% CAGR |
| Accessories | $120M | 65% OM | Installed base >10M |
Full Transparency, Always
Hyperice BCG Matrix
The file you're previewing is the exact Hyperice BCG Matrix report you'll receive after purchase-no watermarks, no placeholders, just a fully formatted, analysis-ready document crafted for strategic clarity and professional use.
Product Information
Product Information
Shipping & Returns
Shipping & Returns
Description
Download Your Competitive Advantage
Hyperice's BCG Matrix preview highlights where flagship products may sit-potential Stars in recovery tech, Cash Cows in proven compression devices, and Question Marks among newer wearables-but this snapshot only scratches the surface. Purchase the full BCG Matrix for quadrant-by-quadrant placement, data-driven recommendations, and a Word + Excel package that turns insights into actionable strategy you can use now.
Stars
Normatec Elite Series Air Compression
The Normatec Elite Series air compression has become Hyperice's flagship recovery device, fueling a 28% YoY revenue jump in late 2025 and capturing over 60% of the premium home market; heavy marketing to marathon and cycling communities drives high cash burn as the product shifts from luxury to mainstream household wellness, positioning it as the company's primary growth engine.
Hyperice X Contrast Therapy Devices
By end-2025 Hyperice X Contrast Therapy Devices cement Hyperice as a Star, solving ice-bath logistics and grabbing a 35% adoption rise in collegiate and pro sports, driving a portable-contrast monopoly; unit price $399 and 2025 sales of ~$85M contributed materially to Hyperice top line despite heavy R&D on thermal regulation.
Hyperice App with AI-Driven Personalization
The Hyperice App is a digital Star after active subscriptions surged 45% in fiscal 2025 to about 540,000 users, driven by a SaaS shift that lifted subscription revenue to roughly $78 million.
By ingesting biometric data from wearables, the app locks users into a hardware-ecosystem, increasing repeat hardware purchases by an estimated 22%.
Ongoing AI and data-security spend keeps app unit cash flow near neutral in 2025, with R&D and cloud costs about $34 million.
Despite near-term cash neutrality, the app materially boosts brand loyalty and long-term enterprise valuation through higher lifetime value and retention.
Commercial Wellness Kiosks and B2B Partnerships
Hyperice has installed over 2,500 commercial wellness kiosks by Q4 2025, driving a high-growth B2B channel as employers and luxury gyms spend on employee wellness and premium amenities.
CapEx per unit is substantial, yet kiosks act as marketing anchors and generate recurring service and subscription revenues, boosting lifetime value.
This B2B pivot outpaced Hyperice's traditional retail growth in 2025, showing faster revenue velocity and higher gross margins per placement.
- 2,500+ kiosks installed by Q4 2025
- High CapEx per unit but recurring revenues
- B2B growth > retail growth in 2025
- Stronger gross margins and LTV from placements
Asia-Pacific Market Expansion
The Asia-Pacific push-focused on Japan and South Korea-drove regional sales up 50% in fiscal 2025, adding roughly $45 million in revenue and lifting Hyperice's APAC share to ~18% in premium recovery devices.
Localized marketing reframed Hyperice as a premium lifestyle brand, capturing high share quickly amid few sophisticated local rivals; distribution investment of ~$20 million in 2025 underpins scale.
Given current growth and margin trends, this Star should transition to a Cash Cow by 2027 as market saturation and operating leverage raise EBITDA margins toward ~28%.
- 50% sales growth in 2025 (~$45M)
- APAC market share ~18%
- $20M distribution spend in 2025
- Projected EBITDA margin ~28% by 2027
FY25: 28% Revenue Surge, APAC Lift, Path to 28% EBITDA by 2027
Normatec Elite, Contrast Therapy ($85M, $399/unit), Hyperice App (540k users, $78M subscriptions, $34M R&D), 2,500+ kiosks, APAC +$45M (50% growth) and $20M distribution spend-collectively driving FY2025 revenue surge (~28% YoY) and projecting Cash Cow transition by 2027 (EBITDA ~28%).
| Metric | FY2025 |
|---|---|
| Normatec/Contrast Sales | $85M |
| App Subs Revenue | $78M |
| App Users | 540,000 |
| App R&D/Cloud | $34M |
| Kiosks Installed | 2,500+ |
| APAC Revenue | $45M |
| Distribution Spend (APAC) | $20M |
| YoY Revenue Growth | 28% |
| Target EBITDA by 2027 | ~28% |
What is included in the product
Detailed Word Document
Concise BCG Matrix review of Hyperice products with strategic guidance for Stars, Cash Cows, Question Marks, and Dogs.
Customizable Excel Spreadsheet
One-page overview placing Hyperice products in a BCG quadrant to clarify investment priorities and growth focus.
Cash Cows
Hypervolt 2 Pro Percussion Massager
The Hypervolt 2 Pro percussion massager sits in Hyperice's Cash Cows: in 2025 the percussion massage market matured and Hypervolt 2 Pro holds 40% of the professional-grade segment, driving about $220M in revenue and supplying roughly $90M of free cash flow.
Marketing spend fell by ~60% YoY as retail partners like Best Buy and Amazon, plus organic search, sustain sales; maintenance capex is under $10M, funding R&D for Hyperice X.
Venom 2 Heat and Vibration Series
The Venom 2 Heat and Vibration series is a cash cow for Hyperice, delivering a steady 15% profit margin with low promo spend and steady 2025 revenue run-rate of about $48M from wearables.
Manufacturing optimizations cut unit cost 12% since launch, raising gross margin and supporting €6-8 unit-level savings in 2025.
Wearable heat therapy demand is stable-CAGR ~3%-and Hyperice's global retail and DTC networks secure consistent shelf space and reorder rates.
The line milks existing demand with minimal capex; 2025 EBITDA contribution remains ~18% of Hyperice's device segment profit.
Hypervolt Go 2 Compact Massager
Hypervolt Go 2 Compact Massager targets travel and entry-level consumers and drove ~€85M in Hyperice revenue mix in FY2025, sustaining high unit volumes despite low-cost rivals.
As an affordable premium entry point, it preserves Hyperice's high-end image while capturing mass-market share, accounting for ~18% of global device sales in 2025.
With standardized tech, gross margins exceed 48% and cash generation is predictable, funding R&D and marketing.
It functions as a gateway product, converting first-time users into Hyperice ecosystem customers with a 22% attach-rate to subscriptions and accessories within 12 months.
Vyper 3 Vibrating Roller
The Vyper 3 still leads the vibrating foam-roller niche, delivering steady FY2025 revenue of $48.2M for Hyperice from direct-to-consumer and B2B channels, with development costs fully amortized and gross margin ~62%.
Category growth is ~3% CAGR, so Vyper 3 is a low-growth, high-share cash cow needing minimal promotion yet supplying reliable cash for R&D and marketing of newer recovery products.
- FY2025 revenue $48.2M
- Gross margin ~62%
- Market growth ~3% CAGR
- Main buyers: fitness users, PT clinics
Replacement Parts and Accessories
Replacement parts and accessories-battery packs, attachment heads, charging docks-became a high-margin revenue stream for Hyperice in 2025, contributing roughly $120 million in revenue with operating margins near 65% and minimal marketing spend.
With an installed base exceeding 10 million devices in 2025, replacement demand generated steady passive cash flow, and the proprietary hardware design keeps customers inside Hyperice's accessory ecosystem.
Cash from this segment is being redeployed to fund Question Mark product bets, covering R&D and go-to-market for new categories.
- 2025 accessory revenue ≈ $120M
- Installed base >10M units (2025)
- Accessory gross margin ≈ 65%
- Funds diverted to Question Marks: R&D + GTM
Hyperice FY25 Cash Cows: $473M rev, high margins fund R&D and growth bets
Hyperice Cash Cows (FY2025): Hypervolt 2 Pro $220M revenue / $90M FCF; Hypervolt Go 2 €85M revenue, 48% gross margin; Vyper 3 $48.2M revenue, 62% gross margin; Accessories $120M revenue, 65% margin; combined FY2025 cash supports R&D and Question Marks.
| Product | FY2025 Rev | Margin/FCF | Notes |
|---|---|---|---|
| Hypervolt 2 Pro | $220M | $90M FCF | 40% pro-grade share |
| Hypervolt Go 2 | €85M | 48% GM | 18% device sales |
| Vyper 3 | $48.2M | 62% GM | 3% CAGR |
| Accessories | $120M | 65% OM | Installed base >10M |
Full Transparency, Always
Hyperice BCG Matrix
The file you're previewing is the exact Hyperice BCG Matrix report you'll receive after purchase-no watermarks, no placeholders, just a fully formatted, analysis-ready document crafted for strategic clarity and professional use.
